Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.71 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.71 |
| ▸ | HTR3B | O95264 | 4/20 | 0.71 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.71 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.71 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | DRD3 | P35462 | 1/20 | 0.63 |
| ▸ | HTR6 | P50406 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | NCF1 | P14598 | 1/20 | 0.56 |
| ▸ | HTR1D | P28221 | 1/20 | 0.55 |
| ▸ | HTR1B | P28222 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30747759 | 1.00 | HTR3A (0.71) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL7711668 | 0.98 | HTR3A (0.69) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL4905371 | 0.98 | HTR3A (0.69) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL12932476 | 0.94 | HTR3A (0.64) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6710534 | 0.93 | HTR3A (0.62) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL1062874 | 0.93 | HTR3A (0.62) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL2349863 | 0.87 | HTR3A (0.69) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL7708526 | 0.85 | HTR3A (0.68) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6928763 | 0.85 | HTR3A (0.54) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL5566877 | 0.84 | ALDH1A1 (0.61) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 465 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106074204-B | A kind of application of genistein derivative in whitening field | 山东理工大学 | 2018-10-23 | — | — | CN | claimed |
| CN-106260498-A | The manufacture method of a kind of Semen Pisi sativi protein peptide and application | 山东理工大学 | 2017-01-04 | — | — | CN | claimed |
| CN-106281935-A | A kind of method promoting neutral protease activity and the application in beer clarification thereof | 山东理工大学 | 2017-01-04 | — | — | CN | claimed |
| CN-106065389-A | A kind of method promoting papain activity and the application in beer clarification thereof | 山东理工大学 | 2016-11-02 | — | — | CN | claimed |
| CN-106011121-A | Method for promoting neutral protease activity and use thereof | 烟台双塔食品股份有限公司 | 2016-10-12 | — | — | CN | claimed |
| CN-106011211-A | Method for preparing pea protein polypeptide powder | 烟台双塔食品股份有限公司 | 2016-10-12 | — | — | CN | claimed |
| EP-1831206-B1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARM INC (US) | 2011-08-24 | — | — | EP | claimed |
| JP-2008521903-A | — | — | 2008-06-26 | — | — | JP | claimed |
| EP-1831206-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006060381-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. | 2006-06-01 | — | — | US | claimed |
| US-20260092134-A1 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | UNIV JOHNS HOPKINS (US) | 2026-04-02 | — | — | US | disclosed |
| US-12527746-B2 | Peptide/particle delivery systems | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-01-20 | — | — | US | disclosed |
| US-12458700-B2 | Amine-containing transfection reagents and methods for making and using same | Life Technologies Corporation (US) | 2025-11-04 | — | — | US | disclosed |
| US-12371522-B2 | Bioreducible poly (beta-amino ester)s for siRNA delivery | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-29 | — | — | US | disclosed |
| EP-0711757-A1 | 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy -pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists | F. Hoffmann-La Roche AG (CH) | 1996-05-15 | — | — | EP | disclosed |
| EP-0322643-B1 | MEDICINES CONTAINING AS A MIXTURE INTERFERON AND 1-DESOXY-PIPERIDINOSES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE | BAYER AG (DE) | 1991-07-24 | — | — | EP | disclosed |
| US-4940705-A | VIRICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-07-10 | — | — | US | disclosed |
| EP-0322643-A1 | Medicines containing as a mixture interferon and 1-desoxy-piperidinoses, process for their manufacture and their use | BAYER AG (DE) | 1989-07-05 | — | — | EP | disclosed |
| EP-0313974-A1 | N-substituted derivatives of 1-desoxynojirimycine and 1-desoxymannonojirimycine, process for their preparation and their use as pharmaceuticals | BAYER AG (DE) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527746-B2 | Peptide/particle delivery systems | VEGFA, IGF2BP2, MSTN | HTR3A 2147/4885HTR3E 1396/4885HTR3B 1999/4885 |
| US-12458700-B2 | Amine-containing transfection reagents and methods for making and using same | SNRPA, NUDT21, SOAT2 | HTR3A 2204/4885HTR3E 2058/4885HTR3B 1563/4885 |
| US-12371522-B2 | Bioreducible poly (beta-amino ester)s for siRNA delivery | AARS1, SLC43A1, PHAX | HTR3A 4002/4885HTR3E 3145/4885HTR3B 3494/4885 |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | KIT, CHUK, TNNI3K | HTR3A 2646/4885HTR3E 3320/4885HTR3B 2852/4885 |
| US-20260092134-A1 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | SLC43A1, SLC7A5, SLC7A1 | HTR3A 4257/4885HTR3E 3569/4885HTR3B 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.